Jody L. Janecek

Jody L. Janecek

Auto-generated profile, based on publicly available information

Jody L. Janecek

Department of Surgery, University of Minnesota, Minneapolis, MN, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Vaccine
Verified
Journal Article
Closed access
KPKah-Whye Peng
Kah-Whye Peng
TCTimothy Carey
Timothy Carey
PLPatrycja Lech
Patrycja Lech
RVRianna Vandergaast
Rianna Vandergaast
MMMiguel Á. Muñoz-Alía
Miguel Á. Muñoz-Alía
SRStephen J. Russell
Stephen J. Russell

5 January 2024 in Science Advances
Verified
Journal Article
Open access
SJScott Hunter Oppler Jr
Scott Hunter Oppler Jr
LSLaura Stone
Laura Stone
DLDavid John Leishman
David John Leishman
JJJody L. Janecek
Jody L. Janecek
MMMeghan E. G. Moore
Meghan E. G. Moore
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
Cell-based therapies hold promise for many chronic conditions; however, the continued need for immunosuppression along with challenges in replacing cells to improve durability or retrieving cells for safety are major obstacles. We subcutaneously implanted a device engineered to exploit the innate transcapillary hydrostatic and colloid osmotic pressure generating ultrafiltrate to mimic interstitium. Long-term stable accumulation of ultrafiltrate was achieved in both rodents and nonhuman primates (NHPs) that was chemically similar to serum and achieved capillary blood oxygen concentration. The majority of adult pig islet grafts transplanted in non-immunosuppressed NHPs resulted in xenograft survival >100 days. Stable cytokine levels, normal neutrophil to lymphocyte ratio, and a lack of immune cell infiltration demonstrated successful immunoprotection and averted typical systemic changes related to xenograft transplant, especially inflammation. This approach eliminates the need for immunosuppression and permits percutaneous access for loading, reloading, biopsy, and recovery to de-risk the use of “unlimited” xenogeneic cell sources to realize widespread clinical translation of cell-based therapies.

15 October 2026 in Stem Cell Reports
Verified
Journal Article
Open access
MRMuhammad Irfanur Rashid
Muhammad Irfanur Rashid
JKJames Kiley
James Kiley
KAKarim Azzag
Karim Azzag
SCSarah B. Crist
Sarah B. Crist
EMEthan Murphy
Ethan Murphy
RPRita Perlingeiro
Rita Perlingeiro
Cell-based regenerative therapies represent a promising platform for muscular dystrophies, but the role of histocompatibility for muscle engraftment remains poorly defined. Given their close genetic relationship to humans, nonhuman primate (NHP) models provide an ideal system to investigate this question. Here, we generated myogenic progenitors from induced pluripotent stem cell (iPSC) lines derived from five major histocompatibility complex (MHC)-typed Mauritian-origin cynomolgus macaques (MCMs). Following extensive characterization, one iPSC clone from each donor was selected for transplantation across distinct MHC matching conditions, including fully matched, partially matched, and mismatched recipient-donor pairs. We found that variation in regenerative potential was primarily donor-intrinsic. Strikingly, fully mismatched donor-derived myogenic progenitors exhibiting high regenerative potential consistently outperformed partially and fully matched grafts across recipients. Our results suggest that, under clinically relevant immunosuppression, donor-intrinsic regenerative potential may outweigh histocompatibility as a determinant of early skeletal muscle engraftment, supporting the development of broadly applicable off-the-shelf allogeneic iPSC-based therapies for muscular dystrophies.